Axsome Therapeutics, Inc.
AXSM
株式のランク
#2368
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to... Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
株価
$155.70
時価総額
$8.16B
変化（1日）
-0.39%
変化（1年）
20.03%
国
US
取引 Axsome Therapeutics, Inc. (AXSM)
カテゴリー
Healthcare
Axsome Therapeutics, Inc.（AXSM）の株価履歴
終値の最高値: $165.91 （2026-10-01）
終値の最安値: $8.99 （2015-11-01）
終値の最安値: $8.99 （2015-11-01）
Axsome Therapeutics, Inc. の株価履歴（2015 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2026 (TTM) | 25.39% |
| 2025 | 62.10% |
| 2024 | 26.95% |
| 2023 | -4.24% |
| 2022 | 118.74% |
| 2021 | -56.59% |
| 2020 | 11.03% |
| 2019 | 2,538.67% |
| 2018 | -44.64% |
| 2017 | -23.67% |
| 2016 | -25.67% |
| 2015 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $536.13 | 25.72% |
US
|
|
| $200.12 | 645.31% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.01 | 8.09% |
NL
|
